Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Health Technology
Sysmex Corp.
- 5,608.00 JPY
- +73.00
- +1.32%
Japan
Dec 17, 2018Ticker
TKS(6869)Prev. close
5,535Market cap (JPY)
1,157.27BMarket cap (USD)
10,203.91MShares
209.08M
In the news
- Robot injections? Makers look to bring automation to health care Apr 16, 2018
- Otsuka invests in startup making iPS-derived blood platelets Dec 25, 2017
- Tomorrow's game: Offshore production with robots Dec 7, 2017
- Japanese firm's robotic surgeon to hit market by 2020 Oct 29, 2017
- Daiichi Sankyo latest in Japan to tap iPS cells Aug 8, 2017 See more articles on Sysmex Corp.
Business Summary
Sysmex Corp. engages in the development, manufacture, import, export, and sale of clinical laboratory instruments, reagents, and software used in in-vitro diagnostics. It also provides clinical laboratory testing of blood, urine, and other specimens. Its products include instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis, and point-of-care (POC) testing. It operates through the following geographical segments: Japan, Americas, EMEA, China, and Asia Pacific. The company was founded on February 20, 1968 and is headquartered in Kobe, Japan.
Financial Highlights
| Mar 2018 | JPY | USD |
| Revenue | 281,935M | 2,543.79M |
| Gross Profit | 158,949M | 1,434.13M |
| Operating income | 59,947M | 540.87M |
| Income before tax | 58,117M | 524.36M |
| Net income | 39,221M | 353.87M |
| EBITDA | 74,590M | 672.99M |
| Diluted EPS | 187.84 | 1.69 |
| Dividends Per Share | 66 | 0.59 |
| Total Assets | 321,979M | 3,027.54M |
| Total liabilities | 80,531M | 757.22M |
| Total equity | 240,750M | 2,263.75M |
| Operating cash flow | 52,240M | 471.34M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 184,538M | 221,376M | 252,622M | 249,899M | 281,935M |
| Gross Profit | 112,728M | 122,383M | 150,690M | 141,777M | 158,949M |
| Operating income | 32,870M | 44,411M | 60,710M | 50,822M | 59,947M |
| Income before tax | 33,451M | 45,727M | 58,274M | 49,623M | 58,117M |
| Net income | 20,573M | 26,638M | 39,278M | 40,635M | 39,221M |
| EBITDA | 46,118M | 57,364M | 72,820M | 63,203M | 74,590M |
| Diluted EPS | 99.16 | 128.02 | 188.30 | 194.74 | 187.84 |
| Dividends Per Share | 27 | 38 | 52 | 58 | 66 |
| Total Assets | 210,758M | 247,983M | 263,917M | 279,817M | 321,979M |
| Total liabilities | 64,508M | 78,433M | 82,864M | 71,248M | 80,531M |
| Total equity | 146,250M | 169,550M | 182,801M | 209,407M | 240,750M |
| Operating cash flow | 36,563M | 38,640M | 41,794M | 32,832M | 52,240M |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 1,842.22M | 2,015.13M | 2,103.70M | 2,307.73M | 2,543.79M |
| Gross Profit | 1,125.34M | 1,114.02M | 1,254.86M | 1,309.26M | 1,434.13M |
| Operating income | 328.13M | 404.26M | 505.56M | 469.32M | 540.87M |
| Income before tax | 333.93M | 416.24M | 485.27M | 458.25M | 524.36M |
| Net income | 205.37M | 242.47M | 327.08M | 375.25M | 353.87M |
| EBITDA | 460.39M | 522.17M | 606.40M | 583.65M | 672.99M |
| Diluted EPS | 0.98 | 1.16 | 1.56 | 1.79 | 1.69 |
| Dividends Per Share | 0.26 | 0.34 | 0.43 | 0.53 | 0.59 |
| Total Assets | 2,046.49M | 2,067.81M | 2,348.12M | 2,511.14M | 3,027.54M |
| Total liabilities | 626.38M | 654.01M | 737.25M | 639.39M | 757.22M |
| Total equity | 1,420.10M | 1,413.80M | 1,626.41M | 1,879.26M | 2,263.75M |
| Operating cash flow | 365.00M | 351.73M | 348.03M | 303.19M | 471.34M |
Valuation Measures
| Mar 2018 | |
| PER | 51.19 |
| ROA | 13.03% |
| ROE | 17.42% |
| Operating margin | 21.26% |
| Profit margin | 13.91% |
Key executives
- Chairman & President: Hisashi Ietsugu
- Manager-Finance: Keishi Matsumoto
- Director, Head-Technology Development & Strategy: Kaoru Asano
- Executive Officer: Yukio Hamaguchi
- Executive Officer: John Kershaw
Shareholders
- Kobe Yamabuki Foundation (5.7%)
- Nakatani Foundation (5.6%)
- Nakatani Kosan YK (5.0%)
- Capital Research & Management Co. (World Investors) (3.2%)
- IETSUGU KAZUKO (2.9%)
- WADA TAEKO (2.9%)
- The Vanguard Group, Inc. (2.2%)
- Estate of Tadashi Nakatani (2.2%)
- ITANI KENJI (2.0%)
- Nomura Asset Management Co., Ltd. (1.9%)
Contact Details
- Website:http://www.sysmex.co.jp
- Address: 1-5-1 Wakinohama-Kaigandori, Chuo-Ku, Kobe, 651-0073, Japan
- Phone: +81.78.265.0500
Related Companies
- Sysmex Medical Electronics (Shanghai) Co., Ltd.
- Sysmex Wuxi Co. Ltd.
- Sysmex Inostics, Inc.
- Sysmex Turkey Diagnostik Sistemleri Ltd. STI
- Sysmex (Malaysia) Sdn.Bhd.
- Sysmex Vietnam Co. Ltd.
- Sysmex Taiwan Co. Ltd.
- Sysmex Suisse AG
- Sysmex Slovakia sro
- Sysmex Shanghai Ltd.
- Sysmex RUS LLC
- Sysmex Polska Sp zoo
- Sysmex Philippines, Inc.
- Sysmex Hungaria Kft.
- Sysmex Hong Kong Ltd.
- Sysmex Espana SL
- Sysmex do Brasil Industria e Comercio Ltda.
- Sysmex CZ sro
- Sysmex Canada, Inc.
- Sysmex Austria GmbH
- Sysmex Middle East FZ LLC
- Sysmex South Africa (Pty) Ltd.
- Sysmex Inostics GmbH
- Sysmex Korea Co., Ltd.
- Katakura Industries Co. Ltd. /Biological Research Center/
- Sysmex RA Co. Ltd.
- Sysmex Europe GmbH
- Sysmex Deutschland GmbH
- Sysmex TMC Co., Ltd.
- Sysmex International Reagents Co., Ltd.
Competitors
- bioMerieux SA
- Haemonetics Corporation
- Bio-Techne Corporation
- Biocept, Inc.
- Epigenomics AG
- Guardant Health, Inc.
Copyright © 2018 FactSet Research Systems Inc. All rights reserved.
Last Updated on 17 Dec, 2018Your full access to the Nikkei Asian Review has expired
